Sepsis-Associated Coagulopathy

1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167-74. doi: 10.1097/CCM.0b013e31827c09f8.10.1097/CCM.0b013e31827c09f8Search in Google Scholar

2. Vincent JL, Marshall JC, Namendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respiratory Med. 2014;2:380-6. doi: 10.1016/s2213-2600(14)70061-x.10.1016/S2213-2600(14)70061-XSearch in Google Scholar

3. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10. doi: 10.1001/jama.2016.0287.10.1001/jama.2016.0287496857426903338Search in Google Scholar

4. Copotoiu SM, Copotoiu R. Much Ado About the New Definitions of Sepsis. J Crit Care Med. 2016;2:67-72. doi: 10.1515/jccm-2016-0015.10.1515/jccm-2016-0015593912929967840Search in Google Scholar

5. Rawal G, Kumar R, Yadav S, Singh A. Anemia in Intensive Care: A review of Current Concepts. J Crit Care Med. 2016;2:109-14. doi: 10.1515/jccm-2016-0017.10.1515/jccm-2016-0017595325029967848Search in Google Scholar

6. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290-295. doi: 10.1016/j.thromres.2011.10.013.10.1016/j.thromres.2011.10.01322061311Search in Google Scholar

7. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2010;30:10-2.10.1055/s-0037-1617143Search in Google Scholar

8. Allen KS, Sawheny E, Kinasewitz GT. Anticoagulant modulation of inflammation in severe sepsis. World J Crit Care Med. 2015;4:105-15. doi: 10.5492/wjccm.v4.i2.105.10.5492/wjccm.v4.i2.105441156225938026Search in Google Scholar

9. Wiersinga WJ, Levi M, van der Poll T. Coagulation in Sepsis. In: Abraham E, Singer M, editors. Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. p. 273-85.Search in Google Scholar

10. Camicia G, Pozner R, de Larranaga G. Neutrophil extracellular traps in sepsis. Shock. 2014;42:286-94. doi: 10.1097/SHK.0000000000000221.10.1097/SHK.000000000000022125004062Search in Google Scholar

11. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125(Suppl1):S70-S73. doi: 10.1016/j.thromres.2010.01.042.10.1016/j.thromres.2010.01.042283900120185165Search in Google Scholar

12. Mackman N. The many faces of tissue factor. J Thromb Haemost. 2009;7(Suppl1):136–9. doi: 10.1111/j.1538-7836.2009.03368.x.10.1111/j.1538-7836.2009.03368.xSearch in Google Scholar

13. Taylor FB, Chang AC, Peer G, et al. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood. 1998;91:1609-15.10.1182/blood.V91.5.1609Search in Google Scholar

14. Carraway MS, Welty-Wolf KE, Miller DL, et al. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med. 2003;167:1200-9. doi: 10.1164/rccm.200204-287OC.10.1164/rccm.200204-287OCSearch in Google Scholar

15. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27:639-51. doi: 10.1055/s-2001-18868.10.1055/s-2001-18868Search in Google Scholar

16. Sovershaev MA, Lind KF, Devold H, et al. No evidence for the presence of tissue factor in high-purity preparations of immunologically isolated eosinophils. J Thromb Haemost. 2008;6:1742-9. doi: 10.1111/j.1538-7836.2008.03105.x.10.1111/j.1538-7836.2008.03105.xSearch in Google Scholar

17. Egorina EM, Sovershaev MA, Olsen JO, Osterud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood. 2008;111:1208-16. doi: 10.1182/blood-2007-08-107698.10.1182/blood-2007-08-107698Search in Google Scholar

18. Rondina MT, Schwertz H, Harris ES, et al. The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. J Thromb Haemost. 2011;9:748-58. doi: 10.1111/j.1538-7836.2011.04208.x.10.1111/j.1538-7836.2011.04208.xSearch in Google Scholar

19. Liu D, Zhang D, Scafidi J, et al. C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood. 2005;105:2350-5. doi: 10.1182/blood-2004-05-1963.10.1182/blood-2004-05-1963Search in Google Scholar

20. Lupu C, Westmuckett AD, Peer G, et al. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol. 2005;167:1161-72. doi: 10.1016/s0002-9440(10)61204-7.10.1016/S0002-9440(10)61204-7Search in Google Scholar

21. Szotowski B, Antoniak S, Rauch U. Alternatively spliced tissue factor: a previously unknown piece in the puzzle of hemostasis. Trends Cardiovasc Med. 2006;16:177-82. doi: 10.1016/j.tcm.2006.03.005.10.1016/j.tcm.2006.03.00516781952Search in Google Scholar

22. van der Poll T. Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care. 2008;12(Suppl 6):S3. doi: 10.1186/cc7026.10.1186/cc7026260711319105796Search in Google Scholar

23. Souza AC, Yuen PS, Star RA. Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int. 2015;87:1100-8. doi: 10.1038/ki.2015.26.10.1038/ki.2015.26444980625692956Search in Google Scholar

24. Reid VL, Webster NR. Role of microparticles in sepsis. Br J Anaesth. 2012;109:503-13. doi: 10.1093/bja/aes321.10.1093/bja/aes32122952169Search in Google Scholar

25. Zafrani L, Gerotziafas G, Byrnes C, et al. Calpastatin controls polymicrobial sepsis by limiting procoagulant microparticle release. Am J Respir Crit Care Med. 2012;185:744-55. doi: 10.1164/rccm.201109-1686OC.10.1164/rccm.201109-1686OC332642322268136Search in Google Scholar

26. Woei AJFJ, van der Starre WE, Tesselaar ME, et al. Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. Thromb Res. 2014;133:799-803. doi: 10.1016/j.thromres.2014.03.007.10.1016/j.thromres.2014.03.00724657035Search in Google Scholar

27. Forest A, Pautas E, Ray P, et al. Circulating microparticles and procoagulant activity in elderly patients. J Gerontol A Biol Sci Med Sci. 2010;65:414-20. doi: 10.1093/gerona/glp187.10.1093/gerona/glp18719942591Search in Google Scholar

28. Mooberry MJ, Bradford R, Hobl EL, et al. Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia. J Thromb Haemost. 2016;14:1031-42. doi: 10.1111/jth.13285.10.1111/jth.13285487012126857798Search in Google Scholar

29. Levi M, Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41:9-15. doi: 10.1055/s-0034-1398376.10.1055/s-0034-139837625590524Search in Google Scholar

30. Yaguchi A, Lobo FL, Vincent JL, Pradier O. Platelet function in sepsis. J Thromb Haemost. 2004;2:2096-102. doi: 10.1111/j.1538-7836.2004.01009.x.10.1111/j.1538-7836.2004.01009.x15613012Search in Google Scholar

31. de Stoppelaar SF, van ’t Veer C, Claushuis TAM, et al. Thrombocytopenia impairs host defense in gram-negative pneumonia–derived sepsis in mice. Blood. 2014;124:3781-90. doi: 10.1182/blood-2014-05-573915.10.1182/blood-2014-05-573915426398525301709Search in Google Scholar

32. Xiang B, Zhang G, Guo L, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun. 2013;4:2657. doi: 10.1038/ncomms3657.10.1038/ncomms3657421731124150174Search in Google Scholar

33. Sonego F, Castanheira FV, Ferreira RG, et al. Paradoxical Roles of the Neutrophil in Sepsis: Protective and Deleterious. Front Immunol. 2016;7:155. doi: 10.3389/fimmu.2016.00155.10.3389/fimmu.2016.00155484492827199981Search in Google Scholar

34. Czaikoski PG, Mota JM, Nascimento DC, et al. Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis. PloS One. 2016;11:e0148142. doi: 10.1371/journal.pone.0148142.10.1371/journal.pone.0148142474398226849138Search in Google Scholar

35. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13:463-9. doi: 10.1038/nm1565.10.1038/nm156517384648Search in Google Scholar

36. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PloS One. 2012;7:e45427. doi: 10.1371/journal.pone.0045427.10.1371/journal.pone.0045427344689923029002Search in Google Scholar

37. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008;34:459-68. doi: 10.1055/s-0028-1092876.10.1055/s-0028-109287618956286Search in Google Scholar

38. Levi M, van der Poll T, Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med. 2012;70:114-20.Search in Google Scholar

39. Levi M. Antithrombin in sepsis revisited. Crit Care. 2005;9:624-5. doi: 10.1186/cc3819.10.1186/cc3819141401916356248Search in Google Scholar

40. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000;95:1117-23.10.1182/blood.V95.4.1117.002k12_1117_1123Search in Google Scholar

41. King EG, Bauza GJ, Mella JR, Remick DG. Pathophysiologic mechanisms in septic shock. Lab Invest. 2014;94:4-12. doi: 10.1038/labinvest.2013.110.10.1038/labinvest.2013.110565628524061288Search in Google Scholar

42. Levi M, Dorffler-Melly J, Reitsma P, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003;101:4823-7. doi: 10.1182/blood-2002-10-3254.10.1182/blood-2002-10-325412609841Search in Google Scholar

43. Tang H, Ivanciu L, Popescu N, et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol. 2007;171:1066-77. doi: 10.2353/ajpath.2007.070104.10.2353/ajpath.2007.070104195947517640967Search in Google Scholar

44. Draxler DF, Medcalf RL. The fibrinolytic system-more than fibrinolysis? Transfus Med Rev. 2015;29:102-9. doi: 10.1016/j.tmrv.2014.09.006.10.1016/j.tmrv.2014.09.00625576010Search in Google Scholar

45. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med. 2012;40:2704-8. doi: 10.1097/CCM.0b013e318258ff30.10.1097/CCM.0b013e318258ff3022732284Search in Google Scholar

46. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005;128:2864-75. doi: 10.1378/chest.128.4.2864.10.1378/chest.128.4.286416236964Search in Google Scholar

47. Binette TM, Taylor FB, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood. 2007;110:3168-75. doi: 10.1182/blood-2007-03-078824.10.1182/blood-2007-03-078824220091117644733Search in Google Scholar

48. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res. 2006;118:205-12. doi: 10.1016/j.thromres.2005.06.007.10.1016/j.thromres.2005.06.00716009400Search in Google Scholar

49. Prakash S, Verghese S, Roxby D, et al. Changes in fibrinolysis and severity of organ failure in sepsis: a prospective observational study using point-of-care test--ROTEM. J Crit Care. 2015;30:264-70. doi: 10.1016/j.jcrc.2014.10.014.10.1016/j.jcrc.2014.10.01425454072Search in Google Scholar

50. Hayakawa M, Sawamura A, Gando S, et al. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res. 2012;130:906-13. doi: 10.1016/j.thromres.2012.01.015.10.1016/j.thromres.2012.01.01522353215Search in Google Scholar

51. Zeerleder S, Schroeder V, Lammle B, et al. Factor XIII in severe sepsis and septic shock. Thromb Res. 2007;119:311-8. doi: 10.1016/j.thromres.2006.02.003.10.1016/j.thromres.2006.02.00316574200Search in Google Scholar

52. de Jonge E, Friederich PW, Vlasuk GP, et al. Activation of Coagulation by Administration of Recombinant Factor VIIa Elicits Interleukin 6 (IL-6) and IL-8 Release in Healthy Human Subjects. Clin Diagn Lab Immunol. 2003;10:495-97. doi: 10.1128/cdli.10.3.495-497.2003.10.1128/CDLI.10.3.495-497.200315495912738659Search in Google Scholar

53. Fiusa MM, Carvalho-Filho MA, Annichino-Bizzacchi JM, De Paula EV. Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective. BMC Med. 2015;13:105. doi: 10.1186/s12916-015-0327-2.10.1186/s12916-015-0327-2442254025943883Search in Google Scholar

54. Kapur R, Zufferey A, Boilard E, Semple JW. Nouvelle cuisine: platelets served with inflammation. J Immunol. 2015;194:5579-87. doi: 10.4049/jimmunol.1500259.10.4049/jimmunol.150025926048965Search in Google Scholar

55. Carestia A, Rivadeneyra L, Romaniuk MA, et al. Functional responses and molecular mechanisms involved in histone-mediated platelet activation. Thromb Haemost. 2013;110:1035-45. doi: 10.1160/th13-02-0174.10.1160/TH13-02-017423965842Search in Google Scholar

56. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemos. 2006;32(Suppl1):49-60. doi: 10.1055/s-2006-939554.10.1055/s-2006-93955416673266Search in Google Scholar

57. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis. 2001;183:1815-8. doi: 10.1086/320723.10.1086/32072311372037Search in Google Scholar

58. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000;95:1124-9.10.1182/blood.V95.4.1124.002k20_1124_1129Search in Google Scholar

59. Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014;2:67. doi: 10.1186/s40560-014-0065-0.10.1186/s40560-014-0065-0433627925705424Search in Google Scholar

60. Georgescu AM, Szederjesi J, Voidăzan S, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) – a possible biomarker for bacteremia in sepsis / Forma solubilă a receptorului pentru activatorul de plasminogen de tip urokinază (suPAR) – un biomarker posibil pentru bacteriemie în sepsis. Rev Romana Med Lab. 2015;23:59-73. doi: 10.1515/rrlm-2015-0002.10.1515/rrlm-2015-0002Search in Google Scholar

61. Szederjesi J, Almasy E, Lazar A, et al. An Evaluation of Serum Procalcitonin and C-Reactive Protein Levels as Diagnostic and Prognostic Biomarkers of Severe Sepsis. J Crit Care Med. 2015;1:143-7. doi: 10.1515/jccm-2015-0022.10.1515/jccm-2015-0022595329529967823Search in Google Scholar

62. Dhainaut JF, Shorr AF, Macias WL, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med. 2005;33:341-8.10.1097/01.CCM.0000153520.31562.4815699837Search in Google Scholar

63. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64. doi: 10.1056/NEJMoa1202290.10.1056/NEJMoa120229022616830Search in Google Scholar

64. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-78.10.1001/jama.286.15.186911597289Search in Google Scholar

65. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47. doi: 10.1001/jama.290.2.238.10.1001/jama.290.2.23812851279Search in Google Scholar

66. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924-33. doi: 10.1111/j.1538-7836.2004.00955.x.10.1111/j.1538-7836.2004.00955.x15550023Search in Google Scholar

67. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90-7. doi: 10.1111/j.1538-7836.2005.01697.x.10.1111/j.1538-7836.2005.01697.x16409457Search in Google Scholar